KRAS and colorectal carcinoma: Notably, colorectal carcinomas with KRAS mutations display a distinct immunoregulatory profile, marked by the pronounced downregulation of immune checkpoints such as BTLA, CTLA-4, and TIGIT—a pattern in sharp contrast to that observed in pulmonary malignancies (111).